Introduction
Pulmonary hypertension (PH) is a life-threatening, multi-factorial disorder characterized by increased pulmonary vascular resistance and remodeling of the small pulmonary arteries, which precipitate right ventricular hypertrophy (RVH) and failure 1, 2 . Despite therapeutic innovation, including the introduction of prostacyclin (PGI 2 ) analogues 3 , endothelin receptor antagonists 4 , and phosphodiesterase 5 inhibitors (PDE5i) 5 mortality remains unacceptably high 6, 7 As such, there is a clear unmet medical need for improved drug efficacy in this disorder.
Loss of endothelial nitric oxide (NO)-and PGI 2 -driven cyclic guanosine-3',5'-monophosphate (cGMP) and cyclic adenosine-3',5'-monophosphate (cAMP) signaling is a hallmark of PH, particularly the pulmonary arterial hypertension (PAH) sub-group (WHO Group 1) 1 . Within the pulmonary circulation, cyclic nucleotides are responsible for mediating endothelium-dependent dilation, thereby maintaining pulmonary vascular homeostasis, but also have salutary actions on pulmonary vascular remodeling, fibrosis, and RV function 8, 9 . Thus, augmenting cyclic nucleotide signaling represents an appealing, proven strategy for improving therapy, and underpins the efficacy of PDEi, PGI 2 analogues and soluble guanylate cyclase (sGC) stimulators 9 . Moreover, combinations of cGMP (e.g. PDE5i) and cAMP-elevating agents (e.g. iloprost or epoprostenol) exert an additive, if not synergistic, beneficial effect in PH patients 10 .
Cyclic nucleotide phosphodiesterases (PDEs) are homologous enzymes that facilitate the breakdown of cAMP and/or cGMP 11 . Within the lung, cGMP-hydrolyzing PDE5 is the most abundant isoform 12 and enzyme expression and activity are up regulated in pre-clinical models of 4 patients 15, 16 , and isoform selective inhibitors are effective in pre-clinical models of PH [17] [18] [19] [20] . One PDE isozyme that has received little or no attention in the setting of PH is PDE2. This 'cGMPstimulated' PDE metabolizes cAMP and cGMP and, akin to PDE5, possesses a GAF domain 21 within its N-terminus 11 that acts as a positive feedback loop to expedite cyclic nucleotide hydrolysis in the presence of cGMP. PDE2 (and splice variants thereof) is expressed in a wide variety of cells and tissues in the cardiovascular system (e.g. myocardium, platelets, endothelium) 11 , and also found in the lung, including pulmonary artery smooth muscle cells from patients with PH 15, 16 . Indeed, the enzyme is functionally active in the pulmonary circulation since inhibition of this isoform has been shown to modulate microvascular permeability 22, 23 and acute hypoxic vasoconstriction in vitro 24 .
We therefore hypothesized that in PH, pulmonary PDE2 activity curtails cytoprotective cGMP-and cAMP-signaling (since it metabolizes both cyclic nucleotides) 11 , and exacerbates pathology. In accord, we investigated the effects of the selective PDE2i, BAY 60-7550 (in vitro IC 50 = 4.7nM; >50-fold selectivity over PDE1, and >100-fold selectivity over other PDE isozymes 25 ), on pulmonary vascular dynamics and pulmonary vascular smooth muscle proliferation in vitro, and etiologically distinct pre-clinical models of PH, to identify beneficial activity of the molecule per se, interactions with endogenous pulmonary protective mediators, and additive effects with existing therapies.
Methods
All studies conformed to the UK Animals (Scientific Procedures) Act 1986 and had approval from a local ethics committee within Barts & The London School of Medicine. Treatment groups, doses and route of administration for in vivo studies are outlined in Supplemental Table 1 . Mice were acute hypoxic vasoconstriction in vitro 24 .
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Hypoxia-induced PH
Male mice (C57BLK/6J; Charles River, UK), or Wild-type (WT) and natriuretic peptide receptor (NPR)-A knockout (KO) littermates (male, 20-25g; C57BLK/6J background) were placed inside a normobaric chamber 26 with 10% oxygen for either 3 weeks with drug treatment from day 1
(Groups 1-6, Supplemental Table 1 ) or 5 weeks hypoxia with drug treatment from day 14 (i.e.
after onset of overt PH to assess the potential of drugs to reverse established pathology; Groups 1-4 & 7-14, Supplemental Table 1 ). Age-matched normoxic control mice were housed in room air.
Bleomycin-induced PH
A second, etiologically distinct model of PH was used to validate the efficacy of BAY 60-7550 in reducing disease severity. Male mice (C57BLK/6J; Charles River, UK) were exposed to bleomycin (2mg/kg, 1ml/kg volume) once by oropharangeal instillation 26 under light isofluorane-induced anesthesia (1.5% isofluorane, 0.2ml/min oxygen). Controls were similarly instilled with sterile saline (1ml/kg). Drug treatments were administered daily over a 3 week period, starting on the day of bleomycin administration.
Mouse haemodynamics
Mice were anaesthetized using isofluorane (1.5%, 0.2ml/min oxygen) & maintained at 37°C. The right ventricular systolic pressure (RVSP) and mean arterial blood pressure (MABP) were measured using a Mikrotip® pressure catheter (size 1F, SPR-1000, Millar Instruments, Houston, TX, USA) and RVH was calculated by weight of RV to left ventricle + septum ratio (RV/(LV+S)) 26 . Plasma was obtained from centrifugation of whole blood (10,000xg, 2min) and assayed for cGMP (cGMP Direct Biotrak EIA, GE Healthcare, Buckinghamshire, UK) and cAMP (cAMP ELISA, Enzo Life Sciences, Exeter, UK).
A second, etiologically distinct model of PH was used to validate the efficacy of f B BAY AY AY 6 6 60-0-0 75 75 7550 50 n reducing disease severity. Male mice (C57BLK/6J; Charles River, UK) were exposed to bl leo eo omy my my i ci cin n n (2 (2 (2mg mg/k /k /kg, g, 1ml/kg volume) once by or r rop op o h h harangeal instil il lla l tion on n 26 26 2 under light s sof f flu luorane-in ndu du uce ce ed an anes es sth th thes es sia ia a ( (1. 1.5% 5% % i is so oflu uor r rane e, , 0 0 0.2ml ml ml/m /m min in n o ox xy yg ge gen) n) ). . C Co Cont nt tro ro ols ls w w wer er re e si s s mi mi mila a larl rly y y n nst st stil il ille le led d wi wi ith th th s ste ter ril le le s sa a alin in ne e (1 1 1ml ml ml/k /k /kg) g) g). D Dr Drug ug ug t t tr re r at at atme me men nt nts we we were re re a ad d dmi mi m ni nist st ster er e e ed ed d dai ai ily ly ly o o ove ve er r r a a 3 3 3 w we week ek k period, starti ing ng ng o on n n th th the e da da d y y of of of b ble le eom om omyc y y in in in a a adm dm dmin in inis is i tr tr t at at atio io i n. n. . 
Immunohistochemistry
Serial sections (4μm) were used for trichrome blue staining and smooth muscle actin ( SMA)
immunohistochemistry. For the latter, sections were stained with mouse monoclonal anti SMA antibody (DAKO, UK, 1:1000 dilution), followed by biotinylated anti-mouse secondary antibody. Immunoreactivity was detected using the ABC-peroxide based system (DAKO, UK).
Stained slides were imaged by Nanozoomer Virtual Microscopy (Hamamatsu, Welwyn Garden City,UK).
Morphological analysis
Transverse formalin fixed lung sections were stained with van Gieson's elastic (EVG) method.
Pulmonary arterial muscularisation was then assessed as we have described previously 27, 28 (see Supplemental Methods).
Vascular function
Aortic and pulmonary artery (3 rd order) rings, isolated from hypoxic (2 weeks, 10% O 2 ) or normoxic (Control) rats (male, Sprague-Dawley, 225-275g) were set up for isometric tension measurement, as we have described previously 26 . For this set of experiments, rat vessels were used to permit concomitant analysis of aorta and pulmonary arteries from the same animals. Pulmonary arterial muscularisation was then assessed as we have described previ vi iou u us sly y y 27, 27, 27, 28 28 28 ( ( (se see Supplemental Methods).
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RT-PCR & Immunoblotting
cDNA was prepared from pulmonary arteries from normoxic and hypoxic rats, and pulmonary artery smooth muscle cells isolated from patients with IPAH and control cells (as above) and analyzed for PDE2A expression using quantitative real-time PCR over 40 cycles (see Supplemental Methods for primer sequence and PCR conditions). PDE2A protein expression was determined by immunoblot using primary anti-PDE2A antibody (Santa Cruz Biotechnology, USA; 1:500) and secondary horse-radish peroxidase conjugated anti-goat IgG antibody (Santa Cruz Biotechnology; 1:10,000). Bands were quantitated by densitometry using ImageJ and normalized to the loading control (anti-actin, 1:20,000, Millipore, Watford, UK. secondary antibody horse-radish peroxidase conjugated anti-mouse IgG, Dako, Cambridge, UK).
PDE2 activity & NO production
PDE2 activity in cytosolic extracts from rat pulmonary arteries and human pulmonary artery smooth muscle cells was determined by the production of 5'-GMP using a commercially available kit (Enzo Life Sciences, Exeter, UK). Total PDE activity was determined using the non-selective PDEi 3-isobutyl-1-methylxanthine (IBMX, 300 mol/L) and specific PDE2 activity calculated as the reduction in 5'-GMP formation in the presence of BAY 60-7550 (1 mol/L).
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Data analysis
Results are expressed as mean±s.e.mean, and P<0.05 denotes significance. The n value denotes the number of animals used in each group. Statistical analyses were performed using GraphPad Prism version 5 as described in each Figure legend .
Results

PDE2 plays a key role in regulating the vasoreactivity of pulmonary arteries
Rats exposed to 2 weeks hypoxia exhibited substantial RVH (Supplemental Figure 1A ) and pulmonary artery (Supplemental Figure 1B) , but not aortic (Supplemental Figure 1C) , endothelial dysfunction compared with normoxic animals, confirming the induction of a PH phenotype. Incubation with BAY 60-7550 sensitized pulmonary arteries from both normoxic ( Figure 1A ) and hypoxic ( Figure 1B ) rats to ANP. Spermine-NONOate-evoked responses were also increased in the presence of BAY 60-7550 ( Figure 1C ), yet this effect was abolished in hypoxic animals ( Figure 1D ). PDE2 inhibition increased the potency of treprostinil in pulmonary vessels from hypoxic ( Figure 1F ), but not normoxic ( Figure 1E ) rats.
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In contrast to PDE2i (Figure 1A-D) , inhibition of PDE1 or PDE3 did not alter ANP or Spermine-NONOate-induced relaxation (Supplemental Table 2 ). Bleomycin-treated mice had increased RVSP ( Figure 3B ) and RV/(LV+S) ratio ( Figure   3D ) compared with saline-treated animals. Akin to the hypoxia model, both RVSP ( Figure 3B) and RV/(LV+S) ratio ( Figure 3D ) were lower in BAY 60-7550-treated mice. Importantly, in both models, MABP was similar in hypoxic mice in the absence and presence of BAY 60-7550
PDE2 inhibition decreases
( Figure 3E, F) , suggesting that this drug exhibits a degree of pulmonary selectivity.
Obligatory role of natriuretic peptide bioactivity in the beneficial effects of PDE2 inhibition in PH
In WT mice, the RVSP was lower in BAY 60-7550-treated hypoxic mice compared with vehicle treated WT animals ( Figure 4A ) but this effect was abolished in NPR-A KO mice ( Figure 4A ).
Likewise the ability of BAY 60-7550 to prevent the RVH in hypoxic WT mice was lost in NPR-A KO animals ( Figure 4C ), suggesting that natriuretic peptide-generated cGMP is regulated by PDE2. Vehicle-treated NPR-A KO mice had elevated MABP compared with vehicle-treated WT animals ( Figure 4E ), but PDE2 inhibition per se did not alter MABP. To assess the effect of the NO pathway on the beneficial activity of BAY 60-7550, WT mice were treated with the NOS inhibitor, L-NAME, for the duration of hypoxia. The ability of BAY 60-7550 to prevent the increased RVSP was maintained in L-NAME-treated animals ( Figure 4B ), suggesting that an intact NO pathway is not necessary for PDE2 inhibition to be effective. BAY 60-7550 also caused a similar reduction in RVH in L-NAME-treated mice, although the NOS inhibitor per se caused an apparent reduction in the RV/(LV+S) ratio, at least in part due to a modest left ventricular hypertrophy resulting from blockade of systemic NO production 31 ( Figure 4D ). L-NAME treatment caused elevated MABP and a significant reduction in the plasma nitrite (NO 2 -) concentrations (index of vascular NO production 30 ; 
Interaction between PDE2 inhibition and natriuretic peptides in PH
The preceding experiments ascertained a pivotal role for natriuretic peptides in the beneficial activity of PDE2i in experimental models of PH. We have recently reported that augmentation of endogenous natriuretic peptide levels using the neutral endopeptidase (NEP; an enzyme that hydrolyses and terminates the biological activity of endogenous natriuretic peptides 32 ) inhibitor ecadotril synergistically interacts with the PDE5i sildenafil to ameliorate PH 26 . Therefore, we investigated whether increasing endogenous natriuretic peptides with ecadotril would also increase the efficacy of BAY 60-7550.
Mice treated with ecadotril alone had RVSP ( Figure 5A ) and RV/(LV+S) ( Figure 5C ) similar to hypoxic vehicle-treated mice. In combination with BAY 60-7550, the hypoxia-induced increases in RVSP and RVH were attenuated, essentially back to control levels ( Figure 5A , C).
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PDE2 inhibition promotes the salutary effects of NO and PGI 2 in PH
Experiments in L-NAME-treated mice suggested that the attenuation of RVSP with PDE2 inhibition is not dependent on endogenous NO. However, we investigated the possibility that a pharmacological interaction between PDE2 inhibition and NO bioactivity may be evident in reversing hypoxia-induced PH. In support of this concept, treatment with inorganic nitrate (which we have shown previously to ameliorate hypoxia-induced PH 28 ), at a dose that was ineffective per se, significantly attenuated the RVSP in combination with PDE2 inhibition ( Figure 6A ). However, this treatment effect was less pronounced against the corresponding RVH ( Figure 6C ).
In parallel experiments, since PDE2 hydrolyses both cGMP and cAMP and PDE2i
augmented the vasorelaxant activity of treprostinil in vitro, we explored if BAY 60-7550 could potentiate the pharmacodynamic effect of treprostinil and reverse established PH. A very similar pattern of activity was observed such that in combination, BAY 60-7550 and treprostinil were able to reverse the hypoxia-induced increase in RVSP, whilst neither intervention as
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PDE2 expression and activity in rodent and human PH
PDE2 mRNA and protein expression were significantly reduced in the pulmonary arteries of hypoxic animals compared to normoxic controls ( Figure 7A , B). Enzyme activity trended towards a lower level but was not significantly different between normoxic and hypoxic arteries ( Figure 7C ). Expression of PDE2 mRNA was also down-regulated in cells from patients with IPAH compared to cells from normal controls ( Figure 7D ). PDE2 activity in cells from IPAH patients was commensurate with that seen in the pulmonary arteries of animals with hypoxiainduced PH ( Figure 7E) ; however, the PDE2 activity observed in pulmonary vascular smooth muscle cells from normal individuals was markedly lower than that in the pulmonary arteries from normoxic control animals, entailing that overall there is little or no reduction in PDE2 activity in PH patients. At the concentration used for in vitro evaluation, BAY 60-7550 caused a significant reduction in PDE activity in both rat pulmonary arteries and pulmonary vascular smooth muscle cells confirming effective inhibition of PDE2 (Figure 7C , E).
PDE2 inhibition regulates the proliferation of pulmonary artery smooth muscle cells from patients with IPAH
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Discussion
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able to recapitulate the vasodilator capacity of sildenafil, indicating that these PDEs do not play a functional role in regulating vascular cGMP turnover (at least in this model system). However, evidence to support our hypothesis that PDE2 plays an active role in pulmonary physiology and PH was provided by the observation that BAY 60-7550 enhanced the vasorelaxant responses to ANP in pulmonary vessels in tissues from both normoxic and hypoxic animals, and increased responses to NO in tissues from normoxic rats. These data raise the possibility that in the hypoxic environment of PH, PDE2i increases pulmonary sensitivity to natriuretic peptides without promoting the vasorelaxant activity of cGMP in the systemic circulation, thereby bringing about a pulmonary specific vasodilator activity. This observation dovetails well with previous reports intimating a role for PDE2 in acute hypoxic vasoconstriction 24 but not in regulating peripheral vascular tone 34 . Vascular reactivity studies also demonstrated that pulmonary PDE2 is involved in modulating cAMP signaling mechanisms, as we hypothesized , and is commensurate with the small reduction in pulmonary artery pressure that sildenafil produces in PH patients 5 . Only using combined therapies, most effectively BAY 60-7550 plus ecadotril, but also BAY 60-7550 plus sildenafil, inorganic nitrate or treprostinil, was a significant salutary effect on RVSP and RVH evident. This advocates the use of such dual approaches in PH to optimize cyclic nucleotide signaling as a treatment strategy and improve on existing therapeutics based on these mechanisms.
We determined that the efficacy of BAY 60-7550 was dependent on intact natriuretic peptide bioactivity, but not on NO-dependent signaling, since the salutary effects of PDE2 inhibition were absent in mice lacking NPR-A (the cognate receptor for ANP and BNP), but maintained in animals treated chronically with L-NAME. As a logical extension, we also established that pharmacological augmentation of natriuretic peptide levels, using the NEP inhibitor ecadotril, in combination with BAY 60-7550 caused an additive, if not synergistic effect, on both the prevention and reversal of hypoxia-induced PH. The efficacy of the combination was dependent on cGMP production and pulmonary selective, providing further evidence that PDE2 inhibition has its most pronounced effect on natriuretic peptide-driven cGMP signaling in PH. These observations parallel recent data derived from studies in models of left ventricular hypertrophy (LVH) and heart failure in which compartmentalized cGMP pools, generated by sGC and particulate (pGC) guanylate cyclases (triggered by NO and natriuretic peptides, respectively) produce distinct effects on myocardial structure and function. These spatially restricted signaling mechanisms are also regulated by distinct PDE isozymes; sGCgenerated cGMP is metabolized predominantly by PDE5 whereas pGC-synthesized cGMP is peptide bioactivity, but not on NO-dependent signaling, since the salutary effect ts s s of of f P PDE DE DE2 2 2 nhibition were absent in mice lacking NPR-A (the cognate receptor for ANP and BNP), but ma main in inta ta tain in ined ed ed i i in n n an n nim im imal a s treated chronically with L L L-N -N -A AME. As a lo ogi g g ca al l ex ex exte t nsion, we also esta a ab blished that at p p ph h harm rm mac c col ol olog og ogic ic cal al a a au ug ugm me men ntat tio ion n of f f n n natri ri iu ur uret etic ic i p pep ep pti ide de l l le ev evel els, s, , u u usi sing ng g t the he he N N NEP EP EP f n nhi hi hibi bi bito to tor r ec ec cad ad adot otr ri ril, , i in n co co omb mbin in nat at tio io ion n n wi wi w th th h B B BAY AY AY 6 6 60-0-75 75 7550 50 0 c cau au aus s sed d d an an n a a add dd ddit it tiv ive, e, e i if f f no no not t sy sy syn n nerg rg rgis s sti tic c effect, on bot oth h h th th t e e e pr pr prev ev even e e ti ti ion on on a and nd nd r rev ev e er er rsa sa sal l l of of of h h hyp yp ypox ox o ia ia i -i ind nd nduc uc uced ed ed P P PH. H. H. T T The he he e e eff ff ffic ic i ac ac cy y y of of of t the he h hydrolyzed primarily by PDE2 35, 36 . It appears that a similar mechanism is active in the RV and pulmonary circulation; PDE2 inhibition promotes the cytoprotective functions of endogenous natriuretic peptides whereas it is necessary to drive the NO-dependent pathway pharmacologically before any effect of PDE2 blockade is observed. This latter phenomenon may result from spill-over of cGMP that would ordinarily be hydrolyzed by PDE5 into a PDE2 regulated pool. This also brings into the spotlight the additive activity between BAY 60-7550
and sildenafil revealed in the present study. This cooperative action was apparent at many different levels; pulmonary artery vasodilatation, RVH, and the proliferation of pulmonary vascular smooth muscle cells from PAH patients. Yet, a compounded effect was not observed in the periphery since MABP remained unchanged in the presence of both inhibitors. This crosstalk between PDE2 and PDE5 therefore appears to be specific to the heart and pulmonary circulation. We conclude that increasing cellular cGMP levels by pharmacological blockade of either PDE2 or PDE5 results in activation of the alternate isozyme as a result of cGMP binding to the analogous N-terminal GAF domains both enzymes possess 11 . Only with combined blockade of both PDE2 and PDE5 is it possible to optimize the beneficial effects of cGMP signaling. This finding is important from a therapeutic standpoint since sildenafil is a first-line treatment for PAH and drug efficacy is likely to be limited by activation of PDE2. Thus, evidence that PDE2 inhibition can produce additional activity above and beyond PDE5 inhibition alone is encouraging, and might explain why a significant cohort of PAH patients do not respond well to sildenafil, or experience a diminution of efficacy over time 37 ; co-administration of a PDE2 inhibitor to this population may be superior.
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http://circ.ahajournals.org/ Downloaded from effect of PDE2 inhibition. Recent work has revealed PDE2 to change its substrate profile in the left ventricle based on the dynamic levels of cGMP and cAMP. Thus, under physiological circumstances PDE2 hydrolyses natriuretic peptide generated cGMP almost exclusively, whereas in the presence of -adrenergic activation PDE2 metabolizes predominantly cAMP, thereby augmenting adrenergic signaling 35, 36, 38 . In the failing heart, PDE2 expression and activity are up-regulated and enzyme inhibition appears to be detrimental because of the inotropic and chronotropic activity driven by cAMP is exacerbated 39 . This is in distinct contrast to the current study in which PDE2 inhibition is clearly beneficial in RVH associated with PH. The 
Morphological analysis
Transverse formalin fixed lung sections were stained with van Gieson's elastic (EVG) method. Pulmonary arterial muscularisation was then assessed as previously 
RT-PCR
Tissue lysate and cells were homogenized using QIAshredder technology and RNA was extracted using a standard extraction kit (Qiagen, UK). RNA was quantified 
